{"doi":"10.1126/science.1177319","title":"Identification of a Primary Target of Thalidomide Teratogenicity","abstract":"<jats:title>Thalidomide Teratogenicity Target</jats:title>\n                  <jats:p>\n                    In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women as a cure for morning sickness, but it was then found to have developmental defects, most obviously, stunted limbs in thousands of babies. Although its use was banned worldwide, thalidomide has since been found to be a valuable treatment for a range of cancers, inflammatory disorders, and leprosy. Several hypotheses have been proposed, but the mechanism of action of thalidomide is unknown. Using zebrafish and chicken as animal models,\n                    <jats:bold>\n                      Ito\n                      <jats:italic>et al.</jats:italic>\n                    </jats:bold>\n                    (p.\n                    <jats:related-article xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"doi\" page=\"1345\" related-article-type=\"in-this-issue\" vol=\"327\" xlink:href=\"10.1126/science.1177319\">1345</jats:related-article>\n                    ) show that the protein cereblon is a primary target of thalidomide. Thalidomide exerts teratogenic effects by binding to cereblon and inhibiting associated enzymatic activity important for limb development. Knowing the mechanism of action of thalidomide should encourage the search for thalidomide derivatives without teratogenic activity.\n                  </jats:p>","journal":"Science","year":2010,"id":648235,"datarank":13.545068116360357,"base_score":7.65491704784832,"endowment":7.65491704784832,"self_citation_contribution":1.1482375571772483,"citation_network_contribution":12.396830559183108,"self_endowment_contribution":1.1482375571772483,"citer_contribution":12.396830559183108,"corpus_percentile":null,"corpus_rank":null,"citation_count":2110,"citer_count":200,"citers_with_citation_signal":200,"citers_with_endowment":200,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":176833,"name":"Hideki Ando","orcid":null,"position":1,"is_corresponding":false},{"id":95202,"name":"Takayuki Suzuki","orcid":"0000-0003-4481-9109","position":2,"is_corresponding":false},{"id":212556,"name":"Toshihiko Ogura","orcid":null,"position":3,"is_corresponding":false},{"id":1689193,"name":"Kentaro Hotta","orcid":null,"position":4,"is_corresponding":false},{"id":1689195,"name":"Yoshimasa Imamura","orcid":null,"position":5,"is_corresponding":false},{"id":718008,"name":"Yuki Yamaguchi","orcid":"0000-0002-0197-614X","position":6,"is_corresponding":false},{"id":138394,"name":"Hiroshi Handa","orcid":"0000-0003-3753-9862","position":7,"is_corresponding":false},{"id":1620865,"name":"Takumi Ito","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Identification of a Primary Target of Thalidomide Teratogenicity","abstract":"<jats:title>Thalidomide Teratogenicity Target</jats:title>\n                  <jats:p>\n                    In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women as a cure for morning sickness, but it was then found to have developmental defects, most obviously, stunted limbs in thousands of babies. Although its use was banned worldwide, thalidomide has since been found to be a valuable treatment for a range of cancers, inflammatory disorders, and leprosy. Several hypotheses have been proposed, but the mechanism of action of thalidomide is unknown. Using zebrafish and chicken as animal models,\n                    <jats:bold>\n                      Ito\n                      <jats:italic>et al.</jats:italic>\n                    </jats:bold>\n                    (p.\n                    <jats:related-article xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"doi\" page=\"1345\" related-article-type=\"in-this-issue\" vol=\"327\" xlink:href=\"10.1126/science.1177319\">1345</jats:related-article>\n                    ) show that the protein cereblon is a primary target of thalidomide. Thalidomide exerts teratogenic effects by binding to cereblon and inhibiting associated enzymatic activity important for limb development. Knowing the mechanism of action of thalidomide should encourage the search for thalidomide derivatives without teratogenic activity.\n                  </jats:p>","is_dataset_classified":null,"base_score":7.65491704784832,"endowment":7.65491704784832,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"20223979","pmcid":null,"openalex_id":"https://openalex.org/W1997952190","authors":[],"funders":[],"total_grants":0,"fwci":39.057,"citation_percentile":0.99926677,"influential_citations":0,"citation_trend":[{"year":2012,"count":67},{"year":2013,"count":103},{"year":2014,"count":98},{"year":2015,"count":112},{"year":2016,"count":100},{"year":2017,"count":103},{"year":2018,"count":127},{"year":2019,"count":122},{"year":2020,"count":179},{"year":2021,"count":173},{"year":2022,"count":184},{"year":2023,"count":183},{"year":2024,"count":191},{"year":2025,"count":185},{"year":2026,"count":92}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.science.org/doi/pdf/10.1126/science.1177319","host_type":"publisher"},{"url":"https://doi.org/10.1126/science.1177319","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/20223979","host_type":"repository"}],"fields_of_study":["Multiple Myeloma Research and Treatments","Protein Degradation and Inhibitors","Ubiquitin and proteasome pathways","Adaptor Proteins, Signal Transducing","Animals","Carrier Proteins","Chick Embryo","Cullin Proteins","DNA-Binding Proteins","Embryo, Nonmammalian","Embryonic Development","Fibroblast Growth Factors","Forelimb","Gene Expression Regulation, Developmental","HeLa Cells","Humans","Mutant Proteins","Peptide Hydrolases","Teratogens","Thalidomide","Ubiquitin-Protein Ligases","Ubiquitination","Zebrafish","Zebrafish Proteins"],"mesh_terms":["Animals","Carrier Proteins","Chick Embryo","DNA-Binding Proteins","Embryo, Nonmammalian","Fibroblast Growth Factors","Forelimb","HeLa Cells","Humans","Peptide Hydrolases","Teratogens","Thalidomide","Zebrafish","Gene Expression Regulation, Developmental","Zebrafish Proteins","Ubiquitin-Protein Ligases","Cullin Proteins","Embryonic Development","Adaptor Proteins, Signal Transducing","Mutant Proteins","Ubiquitination","Hela Cells"],"keywords":["Cereblon","Thalidomide","Ubiquitin ligase","Ubiquitin-Protein Ligases","Ubiquitin","Teratology","Zebrafish","Multiple myeloma","Pharmacology","Biology","Medicine","Fetus","Genetics","Internal medicine","Pregnancy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T02:23:35.618711Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}